{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:05:22Z","timestamp":1793232322419,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacc.2024.06.038","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T10:03:53Z","timestamp":1725876233000},"page":"1107-1118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Genotype-Guided Antiplatelet Therapy"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-9957","authenticated-orcid":false,"given":"Wout W.A.","family":"van den Broek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenden S.","family":"Ingraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa H.","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.06.038_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1399-0004.1999.560401.x","article-title":"Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?","volume":"56","author":"Nebert","year":"1999","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2024.06.038_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2009.04.084","article-title":"Pharmacogenetics in cardiovascular antithrombotic therapy","volume":"54","author":"Mar\u00edn","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib3","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.06.038_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvab018","article-title":"The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"Magavern","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.06.038_bib5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib6","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.038_bib7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehaa1097","article-title":"Patient-tailored antithrombotic therapy following percutaneous coronary intervention","volume":"42","author":"van der Sangen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.038_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A\u00a012-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.038_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2017","journal-title":"Eur J Cardiothoracic Surg"},{"issue":"14","key":"10.1016\/j.jacc.2024.06.038_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehad863","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"45","author":"Byrne","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.038_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.038_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","article-title":"Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"68","author":"Bittl","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/23808993.2020.1768844","article-title":"Pharmacogenetic considerations in antiplatelet therapy","volume":"5","author":"Gurbel","year":"2020","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"10.1016\/j.jacc.2024.06.038_bib14","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2024.06.038_bib15","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.038_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cpt.2039","article-title":"Impact of the CYP2C19\u221717 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"109","author":"Lee","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jacc.2024.06.038_bib17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2024.06.038_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2015.70","article-title":"Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations","volume":"16","author":"Fricke-Galindo","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacc.2024.06.038_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991646","article-title":"Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy","volume":"9","author":"Nguyen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jacc.2024.06.038_bib21","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.06.038_bib22","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.038_bib24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib26","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.038_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12471-016-0873-z","article-title":"Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands","volume":"24","author":"Deiman","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacc.2024.06.038_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent","volume":"225","author":"S\u00e1nchez-Ramos","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.038_bib33","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FJC.0000000000000337","article-title":"Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population","volume":"67","author":"Shen","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2024.06.038_bib35","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002640","article-title":"Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: a pragmatic randomized clinical trial","volume":"13","author":"Tuteja","year":"2020","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.06.038_bib38","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A\u00a0genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jacc.2024.06.038_bib39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jcin.2023.01.356","article-title":"Genetic-guided oral P2Y12 inhibitor selection and cumulative ischemic events after percutaneous coronary intervention","volume":"16","author":"Ingraham","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib40","article-title":"CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings","volume":"11","author":"Beitelshees","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.06.038_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.038_bib43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacc.2024.06.038_bib44","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jcin.2024.03.027","article-title":"P2Y12 inhibition in patients requiring oral anticoagulation after percutaneous coronary intervention: the SWAP-AC\u20132 study","volume":"17","author":"Ortega-Paz","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.jacc.2024.06.038_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40256-021-00496-4","article-title":"Cost effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the POPular Genetics trial","volume":"22","author":"Claassens","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2024.06.038_bib46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41397-020-0162-5","article-title":"Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data","volume":"20","author":"Limdi","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.jacc.2024.06.038_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jth.12059","article-title":"Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis","volume":"11","author":"Lala","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jacc.2024.06.038_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ehjcvp\/pvac037","article-title":"Cost-effectiveness of clopidogrel versus ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome","volume":"9","author":"van den Broek","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2024.06.038_bib49","series-title":"Role for genotype testing to guide antiplatelet selection after percutaneous coronary intervention","author":"Ingraham","year":"2022"},{"key":"10.1016\/j.jacc.2024.06.038_bib50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamainternmed.2018.0783","article-title":"Trends in platelet adenosine diphosphate P2Y 12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016","volume":"178","author":"Dayoub","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib51","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.038_bib52","series-title":"Annotation of CPIC guideline for\u00a0clopidogrel and CYP2C19","year":"2022"},{"key":"10.1016\/j.jacc.2024.06.038_bib53","series-title":"Table\u00a0of pharmacogenetic associations","year":"2022"},{"issue":"24","key":"10.1016\/j.jacc.2024.06.038_bib54","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib55","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2024.06.038_bib56","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpt.630","article-title":"The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems","volume":"102","author":"Luzum","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2024.06.038_bib58","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cpt.1006","article-title":"Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy","volume":"104","author":"Empey","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2024.06.038_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009434","article-title":"Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: a POPular genetics subanalysis","volume":"14","author":"Claassens","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcin.2020.01.219","article-title":"Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI","volume":"13","author":"Hulot","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/10742484231210704","article-title":"The clinical implementation of CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry","volume":"28","author":"Azzahhafi","year":"2023","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2024.06.038_bib62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","article-title":"Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"Cavallari","year":"2018","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib63","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.06.038_bib64","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2015.03.567","article-title":"Bleeding avoidance strategies during percutaneous coronary interventions","volume":"65","author":"Singh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.038_bib65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.038_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73871-x","article-title":"Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis","volume":"10","author":"Fei","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2024.06.038_bib67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/dmpt-2018-0017","article-title":"Personalized medicine into health national services: barriers and potentialities","volume":"33","author":"Rodr\u00edguez Vicente","year":"2018","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.jacc.2024.06.038_bib68","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.13779","article-title":"A\u00a0paradigm shift in pharmacogenomics: from candidate polymorphisms to comprehensive sequencing","volume":"131","author":"Zhou","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724078938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724078938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T20:01:55Z","timestamp":1758139315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724078938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0735109724078938"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.038","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype-Guided Antiplatelet Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}